PCV68 POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO RECLASSIFY PATIENTS WITH AN INTERMEDIATE RISK BASED ON THE FRAMINGHAM RISK SCORE INTO A LOWER OR HIGHER CATEGORY TO OPTIMIZE STATIN THERAPY
Abstract
Authors
LT Burgers WK Redekop JL Severens